SAB Biotherapeutics, Inc. Common Stock (SABS) is a publicly traded Healthcare sector company. As of September 22, 2026, SABS trades at $3.48 with a market cap of $319.36M and a P/E ratio of 15.64. SABS moved +1.92% today. Year to date, SABS is -9.36%; over the trailing twelve months it is +37.25%. Its 52-week range spans $1.00 to $6.60. Analyst consensus is strong buy with an average price target of $12.67. Rallies surfaces SABS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for SABS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $3.48 |
| Market Cap | $319.36M |
| P/E Ratio | 15.64 |
| EPS | $0.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.60 |
| 52-Week Low | $1.00 |
| Volume | 14.99K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $13.27M |
| Gross Margin | 0.00% |
3 analysts cover SABS: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.67.